Manuscripts. The number of manuscripts we receive continues to increase every year. We received 3,589 manuscripts in 2003. This is a 15% increase over 2002. We are on a trajectory that will reach over 4,000 manuscripts in 2004. Web access of www. neurology.org has also increased steadily. In 2000, there were 40,000 accesses and in 2004 that number grew to 480,000 accesses. This access includes full text, abstracts, searches, Clinical trials recruiting. Neurology will continue to list clinical trial recruiting line notices at no cost. This section is available both in print and online. The online version provides direct links to registries and research sites. We currently have more than 80 trials listed, organized by subspecialty. We expect that these listings will help those conducting clinical trials to more readily recruit patients. Display ads are also available for a reasonable rate. For detailed information on placing a clinical trial line listing or display ad, please see the Web page: http://www.neurology.org/clinicaltrials/?ckϭnck.
Change in author disclosure forms. Neurology will no longer require forms from all authors. Instead, corresponding authors of submitted manuscripts must now sign the Corresponding Author Disclosure form for themselves and on behalf of all authors and send it to Neurology. Co-authors must sign a Co-author Disclosure Form, which is kept by the Corresponding author for a period of 5 years from submission of the manuscript. This change in disclosure forms will allow manuscripts to be processed more quickly in the Neurology editorial office.
Conversion of pre-1999 Neurology to e-format. This initiative will place all back content of Neurology online starting with the January-February issue of 1951. It will be searchable, and we expect to archive back content on CD-ROM for those who wish to purchase this for their libraries.
International editions. We currently have Spanish, Italian, Polish, and Japanese editions of the Journal. The Polish edition Editors Anna Czlonkowska (Warsaw) and Zbigniew Wszolek (Jacksonville) will begin publishing Polish commentary on certain Neurology articles. We expect that other international editions will follow their lead. This international commentary will be written by a Polish-speaking neurologist and will consider aspects of the article that are unique to or characteristic of Poland. The Polish Editors have appointed an editorial board including four neurologists whose native language is Polish.
Online activation. We encourage print readers to activate their online subscription. Users can access www.neurology.org and select the "login instructions" link provided on the Help screen. This will lead users to a step-by-step activation process. The online journal includes full text (pdf and html formats) of articles from 1999 forward, links to PubMed, and extensive search capabilities. It also includes features not available in the print version, including rapidly posted Correspondence, CME, Video, Patient Page, Resident and Fellow Page, and Supplemental Data.
New patient magazine. Following the success of Neurology's Patient Page under Editor Robin Brey, the American Academy of Neurology (AAN) is launching a new publication, Neurology Now, a quarterly direct-to-patient magazine that provides cutting-edge information about advances in the management and treatment of neurological diseases in lay language. The new magazine is edited by Dr. Brey. AAN members have said that one of their greatest needs is to have help in providing credible information about neurological diseases to their patients. Neurology Now has been developed to meet that need.
Disclosures. The World Association of Medical
Editors (WAME) has stated that Editors should disclose their conflicts of interests every year. 2 We plan to do this in the January Editorial Message.
Editor-in-Chief. The Editor-in-Chief, Robert C. Griggs, receives grant funding from the NINDS, the Office of Rare Diseases, and the Muscular Dystrophy Association. The Editor-in-Chief serves on the Medical Advisory Board of Astra-Zeneca but does not retain honoraria from Astra-Zeneca.
